Strategic Partnerships Corgenix is a CAP/CLIA accredited contract development and manufacturing organization with a history of strategic collaborations across the IVD lifecycle, indicating strong potential as a partner for biotech and pharma companies seeking end-to-end testing solutions, regulatory support, and manufacturing scalability.

Clinical Testing Demand With capabilities in clinical studies, trial management, and physician-ordered patient testing, there are opportunities to upsell comprehensive clinical testing services to biotech start-ups and oncology-focused centers developing rapid diagnostics or companion diagnostics.

Regulatory Expertise ISO-13485:2016, FDA-registered facility and GMP-compliant operations position Corgenix as a trusted supplier for regulated diagnostic products, making them attractive to companies requiring compliant manufacturing and quality control for IVD solutions.

Funding & Health Trends Past NIH funding for rapid Ebola diagnostics and collaborations with major pharma players (e.g., Lilly) signal alignment with high-impact, fast-moving infectious disease and oncology diagnostic programs, suggesting potential for grant-backed projects and joint development opportunities.

Market Positioning Serving biotech companies, pharma, cancer centers, and academic labs with global warehousing and distribution capabilities, Corgenix can be positioned as a versatile, one-stop partner for testing deployment, scale-up, and international regulatory support.